JP2016504315A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016504315A5 JP2016504315A5 JP2015547441A JP2015547441A JP2016504315A5 JP 2016504315 A5 JP2016504315 A5 JP 2016504315A5 JP 2015547441 A JP2015547441 A JP 2015547441A JP 2015547441 A JP2015547441 A JP 2015547441A JP 2016504315 A5 JP2016504315 A5 JP 2016504315A5
- Authority
- JP
- Japan
- Prior art keywords
- dengue
- immunogenic composition
- combination
- virus
- trivalent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000002163 immunogen Effects 0.000 claims 74
- 239000000203 mixture Substances 0.000 claims 74
- 206010012310 Dengue fever Diseases 0.000 claims 64
- 208000025729 dengue disease Diseases 0.000 claims 64
- 208000001490 Dengue Diseases 0.000 claims 62
- 241000725619 Dengue virus Species 0.000 claims 36
- 230000002238 attenuated effect Effects 0.000 claims 15
- 238000000034 method Methods 0.000 claims 10
- 241000710815 Dengue virus 2 Species 0.000 claims 4
- 241000700605 Viruses Species 0.000 claims 3
- 238000007918 intramuscular administration Methods 0.000 claims 2
- 238000007920 subcutaneous administration Methods 0.000 claims 2
- 229960005486 vaccine Drugs 0.000 claims 2
- 208000032825 Ring chromosome 2 syndrome Diseases 0.000 claims 1
- 101710172711 Structural protein Proteins 0.000 claims 1
- 108010087302 Viral Structural Proteins Proteins 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 230000003053 immunization Effects 0.000 claims 1
- 238000002649 immunization Methods 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000003472 neutralizing effect Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261737679P | 2012-12-14 | 2012-12-14 | |
| US61/737,679 | 2012-12-14 | ||
| PCT/US2013/073757 WO2014093182A1 (en) | 2012-12-14 | 2013-12-07 | Compositions, methods of administration and uses for trivalent dengue virus formulations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016504315A JP2016504315A (ja) | 2016-02-12 |
| JP2016504315A5 true JP2016504315A5 (OSRAM) | 2017-01-26 |
Family
ID=50934851
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015547441A Pending JP2016504315A (ja) | 2012-12-14 | 2013-12-07 | 三価デングウイルス製剤に関する組成物、投与方法および使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US9878031B2 (OSRAM) |
| EP (1) | EP2931310A4 (OSRAM) |
| JP (1) | JP2016504315A (OSRAM) |
| CA (1) | CA2933472A1 (OSRAM) |
| WO (1) | WO2014093182A1 (OSRAM) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2933970T3 (es) * | 2013-03-15 | 2023-02-15 | Takeda Vaccines Inc | Composiciones y métodos para construcciones quiméricas de virus del dengue en vacunas |
| WO2016130786A2 (en) * | 2015-02-15 | 2016-08-18 | Integral Molecular, Inc. | Flaviviridae proteins and virions and methods of use thereof |
| CA3020484A1 (en) | 2016-04-13 | 2017-10-19 | Takeda Vaccines, Inc. | Compositions and methods of vaccination against dengue virus in children and young adults |
| US11426461B2 (en) | 2018-09-05 | 2022-08-30 | Takeda Vaccines, Inc. | Methods for preventing dengue and hepatitis A |
| US11464815B2 (en) | 2018-09-05 | 2022-10-11 | Takeda Vaccines, Inc. | Dengue vaccine unit dose and administration thereof |
| CA3111332A1 (en) * | 2018-09-05 | 2020-03-12 | Takeda Vaccines, Inc. | Dengue vaccine unit dose and administration thereof |
| AU2020331884B2 (en) * | 2019-08-16 | 2025-01-23 | Takeda Vaccines, Inc. | Methods for preventing dengue and Hepatitis A |
| WO2024108087A1 (en) * | 2022-11-18 | 2024-05-23 | Takeda Vaccines, Inc. | A method for determining the proportion of a live, attenuated flavivirus having a nucleotide sequence comprising at least one attenuation locus in a formulation |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2278012T3 (en) | 2000-02-16 | 2015-12-07 | Us Government | Immunogenic dengue 2 virus chimeras |
| US20040120964A1 (en) | 2001-10-29 | 2004-06-24 | Mikszta John A. | Needleless vaccination using chimeric yellow fever vaccine-vectored vaccines against heterologous flaviviruses |
| AU2003239932A1 (en) | 2002-05-31 | 2003-12-19 | Acambis, Inc. | Tetravalent dengue vaccines |
| JP4993301B2 (ja) | 2004-10-20 | 2012-08-08 | サノフィ パスツール バイオロジクス リミテッド ライアビリティ カンパニー | 日本脳炎ウイルスおよび西ナイルウイルスに対するワクチン |
| KR101536612B1 (ko) * | 2005-06-17 | 2015-07-14 | 사노피 파스퇴르 | 약독화된 뎅기 혈청형 1 균주 |
| MX2007015872A (es) | 2005-06-17 | 2008-04-21 | Sanofi Pasteur | Cepa atenuada del serotipo 2 del dengue. |
| AU2006280144B2 (en) * | 2005-08-10 | 2012-06-14 | Sanofi Pasteur Biologics, Llc | Vaccination against dengue virus infection |
| LT2589602T (lt) | 2006-08-15 | 2016-10-10 | The Government Of The U.S.A., As Repr. By The Secretary, Dept. Of Health & Human Services, The Nat. Inst. Of Health | Dengė viruso vakcinos komponentų gavimas |
| FR2906724B1 (fr) * | 2006-10-04 | 2009-03-20 | Sanofi Pasteur Sa | Methode d'immunisation contre les 4 serotypes de la dengue. |
| US20100316670A1 (en) | 2007-06-14 | 2010-12-16 | Blaney Joseph E | Chimeric sle/dengue type 4 antigenic viruses |
| WO2010085358A2 (en) | 2009-01-23 | 2010-07-29 | The Board Of Regents Of The University Of Texas System | Flaviviruses expressing the prm, e, and ns1 proteins of other flaviviruses and uses thereof |
| NZ618158A (en) * | 2009-06-01 | 2015-05-29 | Takeda Vaccines Inc | Compositions and methods for administration of vaccines against dengue virus |
| US8968996B2 (en) * | 2009-06-01 | 2015-03-03 | Takeda Vaccines, Inc. | Compositions and methods for rapid immunization against dengue virus |
| US20120294889A1 (en) | 2010-11-12 | 2012-11-22 | Paxvax, Inc. | Chimeric Flavivirus Vaccines |
| NZ630831A (en) | 2012-06-10 | 2019-02-22 | Takeda Vaccines Inc | Compositions and methods for administration of vaccines against dengue virus |
-
2013
- 2013-12-07 CA CA2933472A patent/CA2933472A1/en not_active Abandoned
- 2013-12-07 EP EP13863155.1A patent/EP2931310A4/en not_active Withdrawn
- 2013-12-07 US US14/652,066 patent/US9878031B2/en not_active Expired - Fee Related
- 2013-12-07 WO PCT/US2013/073757 patent/WO2014093182A1/en not_active Ceased
- 2013-12-07 JP JP2015547441A patent/JP2016504315A/ja active Pending
-
2017
- 2017-12-15 US US15/844,030 patent/US20180228887A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016504315A5 (OSRAM) | ||
| JP2013542224A5 (OSRAM) | ||
| JP2019151636A5 (OSRAM) | ||
| JP2015535302A (ja) | ビリオン分解に影響を及ぼすフラビウイルスのエンベロープタンパク質変異 | |
| KR20130138789A (ko) | 재조합 서브유닛 뎅기 바이러스 백신 | |
| NZ597000A (en) | Compositions and methods for administration of vaccines against dengue virus | |
| JP2017526689A5 (OSRAM) | ||
| EP3474891B1 (en) | Vaccine compositions comprising an attenuated mutant zika virus | |
| Sim et al. | Induction of neutralizing antibodies against dengue virus type 2 upon mucosal administration of a recombinant Lactococcus lactis strain expressing envelope domain III antigen | |
| US9861692B2 (en) | Dengue virus vaccine compositions and methods of use thereof | |
| WO2017156511A8 (en) | Live attenuated zika virus vaccine | |
| KR20170075775A (ko) | 백신 및 진단제 개발을 위한 재조합 뎅기 바이러스에 대한 방법 및 조성물 | |
| EP3590955A1 (en) | Methods and compositions for dengue virus vaccines | |
| EP3236997B1 (en) | Dengue virus vaccine compositions and methods of use thereof | |
| Zheng et al. | Evaluation of a DNA vaccine candidate expressing prM-E-NS1 antigens of dengue virus serotype 1 with or without granulocyte-macrophage colony-stimulating factor (GM-CSF) in immunogenicity and protection | |
| EP3481848B1 (en) | Genomic sequences encoding for an attenuated mutant zika virus | |
| JP5657204B2 (ja) | デングウイルスのカプシドタンパク質を有する、デングウイルスに対する防御反応を誘導することができる医薬品組成物 | |
| CN103352047B (zh) | 旋毛虫肌幼虫es抗原基因疫苗及其制备方法 | |
| Li et al. | Comparison of the efficacy and safety of different immunization routes induced by human respiratory syncytial virus F protein with CpG adjuvant in mice | |
| JP2014524450A5 (OSRAM) | ||
| López et al. | New evidence on the virus capsid as a vaccine candidate against the Dengue 2 virus without the induction of the neutralizing antibodies | |
| Caine | Understanding host adaptation and disease progression of enterovirus 71 using mouse models, reverse genetics, and in vivo imaging | |
| TH91621B (th) | วิธีการของการก่อภูมิคุ้มกันโรคเพื่อต่อต้าน 4 ซีโรไทป์ของไข้เลือดออก | |
| TH138884A (th) | วัคซีนต้านกลุ่มอาการโรคของระบบสืบพันธุ์และทางเดินหายใจในสุกรชนิดก่อโรคได้สูง (hp prrs) |